Idylla EGFR Lung Trial
This retrospective, observational study will compare the results of a BioCartis' EGFR mutation test on the Idylla platform with test results from SoC pathology results from tissue biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. Up to 150 samples will be tested and compared with existing results.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 14, 2021 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Anthony Magliocco
- Interventions being studied
- Diagnostic Test: Idylla EGFR Mutation Test
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patients diagnosed with primary lung cancer
- Data from primary diagnosis must be included in pathology report or data entry.
- Detailed pathology report included for all samples
- Limited or no tissue available
- Only tissue available is from fine needle aspiration
- Tissue blocks older than 5 years old
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- 6555 Sanger Rd, Suite 260Orlando, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 14, 2021. Always confirm current availability with the study team.